Core Insights - The article emphasizes the importance of sustainable future cash flow as a key investment principle, focusing on sectors that are expected to benefit from this trend [1][2]. Group 1: Investment Philosophy - The investment philosophy centers around the principle that future cash flow should balance growth potential and risk control [2]. - Cash flow is viewed from a macro perspective, tracking the ultimate destination of funds rather than being limited to financial statements [2]. - The performance of growth stocks in the A-share market is linked to the certainty of future cash flows, with examples like optical module stocks demonstrating this principle [2][3]. Group 2: Sector Focus - The four main sectors identified for investment opportunities include: - **Internet Sector**: Increasing reliance on internet platforms for work and life leads to stable cash flow advantages [4]. - **Innovative Pharmaceuticals**: Overseas companies are acquiring early-stage options for innovative drugs in China, providing stable cash flow to this sector [5]. - **Shipping Sector**: Global trade volumes remain stable, with opportunities arising from transshipment trade, supporting cash flow in the shipping industry [5]. - **Export Chain**: Export companies benefit from nominal growth in overseas economies while maintaining cost advantages domestically, enhancing competitiveness [5]. Group 3: Valuation and Portfolio Management - The investment strategy involves a balanced industry allocation with slight tilts towards favored sectors, while also identifying undervalued reversal opportunities [3]. - Valuation is a primary consideration in selecting specific stocks, with a focus on dynamic tracking to assess the reasonableness of valuations [3]. - Adjustments to the portfolio are made when performance growth or future orders do not align with current valuation increases [3].

□本报记者 王鹤静 面对资本市场的风云变幻，寻找投资逻辑的内在共性将为构建组合提供指向。淳厚基金权益投资部基金 经理陈印从金融思维入手，立足于未来现金流能够尽可能兼顾成长性和确定性的第一性原理，致力于挖 掘成长与周期风格中的估值抬升机会。 日前，陈印接受了中国证券报记者的专访。围绕着未来现金流可持续增长这一重要投资思路，陈印认 为，未来社会工作生活愈发倚重的互联网平台、获得海外商务拓展的创新药公司、贸易增长惠及的海运 链以及出口链公司等，都是目前的重点关注方向。 关注未来现金流 为拓展自己的投资能力圈，陈印以金融思维为切口，在中观层面积极挖掘行业之间的共通之处。总结下 来，陈印的投资第一性原理就是，未来现金流能够尽可能兼顾成长性和风险控制。 对于现金流的定义，陈印并不狭义地局限于财务报表当中披露的现金流情况，而是将视野放得更加宏 观，跟踪资金的最终去向。 "回过头来看，A股市场每个阶段的成长股，背后都有未来现金流的确定性在里面。以今年以来涨幅靠 前的光模块标的为例，虽然涨幅已经足够大，但是我们能看到业绩是可以兑现的，支撑因素就是其客户 充分的支付意愿，总体上使得行业大概率能够保障未来持续的现金流入。并且，这些 ...

Group 1 - The current market index is at a similar level to 2015, but with significantly better quality and lower valuation, indicating that there is no need to overly focus on the index points themselves [1] - Structural opportunities still exist in various sectors such as new energy, chemicals, consumer electronics, resources, and machinery, despite short-term investor caution primarily in the technology sector [1] - The focus for the remainder of the year should be on structural adjustments, with recommendations to invest in traditional manufacturing upgrades, Chinese companies going abroad, and edge AI [1] Group 2 - The overall growth is entering a recovery cycle, with improvements in net profit margins across various sectors due to accelerated overseas expansion and the implementation of anti-involution measures [2] - The performance of large and mid-cap stocks, which are closely related to the overall economy, shows greater earnings elasticity, indicating a positive trend in China's asset growth [2] - Certain sectors, including emerging technology and cyclical industries, are in a recovery and expansion phase, while others face excess supply pressures [2] Group 3 - The A-share market is expected to experience a period of horizontal adjustment due to the exhaustion of previous upward momentum and the upcoming policy vacuum [4] - The electronic industry and innovation sectors have seen record high allocations in fund reports, suggesting potential structural adjustments in the market [4] - Key investment areas include coal, oil and gas, new energy, non-bank financials, public utilities, media, food and beverage, and transportation [4] Group 4 - The market trend remains positive, supported by macro policies and resilient fundamentals from third-quarter earnings reports [5] - Technology companies with real technological barriers and those aligned with national strategies are expected to be key investment themes [5] - The construction of projects is anticipated to enhance the industrial chain, benefiting companies through increased orders and performance releases [5] Group 5 - The focus is shifting from macro risks to internal structural optimization following the completion of the third-quarter reports and the resolution of U.S.-China trade discussions [6] - The AI sector remains a mid-term industry focus, with potential for rotation within growth sectors [6] - Attention is drawn to industries such as non-ferrous metals, AI applications, power storage, and emerging themes like controlled nuclear fusion and commercial aerospace [6] Group 6 - The market is expected to experience short-term fluctuations and adjustments, with a long-term optimistic outlook due to stable internal and external policies [7] - The new profit growth cycle has begun, with a focus on low-base sectors that may release greater elasticity next year [7] - The technology sector's high allocation in institutional portfolios indicates a need to monitor performance and potential shifts in investment strategies [7] Group 7 - The market is undergoing a rebalancing phase, with a high concentration of active equity fund holdings in the TMT sector, indicating a shift in investor sentiment [8] - There is a growing skepticism towards capital expenditure expansion in overseas markets, while domestic industries are expected to benefit from improved operational conditions [8] - Attention is recommended for upstream resources and sectors benefiting from domestic price stabilization and economic recovery [8] Group 8 - The technology growth sector is experiencing a slowdown in short-term over-allocation, leading to increased volatility [9] - The TMT sector's allocation by funds has reached historical highs, indicating a strong focus on technology growth as a primary market driver [10] - The potential for further increases in fund allocations to the TMT sector suggests ongoing interest and investment opportunities in technology [10] Group 9 - The expectation of a shift from strategic decoupling to a phase of cooperation between the U.S. and China is likely to enhance risk appetite for RMB assets [11] - The market is not expected to experience a straightforward upward trajectory, but the overall bullish sentiment remains intact despite potential high-level fluctuations [11] - The focus on low-position cyclical sectors and overseas opportunities is anticipated to be a key investment strategy moving forward [11]

Core Viewpoint - The Shanghai Composite Index has broken through the 4000-point mark, indicating a potential new round of a "healthy slow bull" market driven by the recovery of market confidence and structural changes in the economy [1]. Market Drivers - The primary driver for the recent market rise is the restoration of confidence in the capital market, supported by favorable policies and improved corporate earnings [18][19]. - Liquidity improvement and industry logic, particularly in technology sectors like AI and renewable energy, are significant factors driving the market [19][20]. - The market's upward movement is attributed to a combination of macroeconomic improvements, positive policy expectations, and an increase in risk appetite [19]. Sources of Incremental Capital - Incremental capital is mainly coming from long-term institutional funds, social security, and the transfer of household savings into equity markets [20][21]. - The current funding structure is healthier compared to previous years, with a notable increase in the proportion of long-term patient capital [22][23]. Main Investment Themes - The technology growth sector remains the primary focus, with AI expected to be a significant opportunity over the next 3 to 5 years [24][25]. - There is an expectation of a balanced market style, with potential shifts between growth and value sectors [27]. Policy Impact - The "policy combination" has played a crucial role in stabilizing market expectations and boosting investor confidence [28][29]. - Continuous and coordinated policy efforts have successfully shaped market sentiment and provided a foundation for the current market rally [30]. Potential Risks - The primary risk identified is the possibility of global macroeconomic growth falling short of expectations, which could impact corporate earnings [31][32]. - High valuation sectors may face risks if actual earnings do not meet market expectations, leading to potential corrections [33]. Investment Strategy Recommendations - It is advised to shift from aggressive investment strategies to optimizing portfolio structures, focusing on defensive and growth balance [34][35]. - Investors are encouraged to maintain a diversified asset allocation to mitigate risks associated with concentrated positions in overheated sectors [36]. Conditions for a "Healthy Slow Bull" Market - The conditions for a new "healthy slow bull" market are in place, including stable blue-chip stocks, strong long-term capital inflows, and a low current allocation of household assets to equities [36][37]. - A stable operating environment for businesses and improved investor risk tolerance are essential for solidifying long-term market trends [38].

Core Viewpoint - The innovative drug sector is experiencing rapid development driven by policy support, patent breakthroughs, and an improving ecosystem, making it a long-term investment opportunity [1] Group 1: Industry Trends - The innovative drug industry is increasingly integrated into the global pharmaceutical supply chain, with Chinese companies playing a significant role in drug research and development [1][3] - The market share of Chinese innovative drug companies is growing, indicating a positive long-term outlook for the sector [1][3] Group 2: Investment Strategy - The investment approach combines top-down and bottom-up strategies, focusing on high-quality companies with positive fundamental trends to achieve better returns [2] - A balanced allocation strategy is employed to mitigate risks associated with individual sectors or stocks, along with strict adherence to stop-loss rules [2] Group 3: Technological Advancements - The continuous development of AI technology is enhancing efficiency in basic research and optimizing drug design and clinical trial processes [3] - AI is being utilized by innovative drug companies to screen and advance drug development, with some products already entering clinical validation stages [3] - Significant breakthroughs are anticipated in drug design and development, particularly for cancer and autoimmune diseases, as well as advancements in gene therapy for metabolic diseases [3]

Core Insights - The article discusses the challenge of achieving both performance and scale growth for large-cap active equity funds in the context of a rising equity market over the past year [1] Group 1: Performance of Large-Cap Active Equity Funds - As of the third quarter, there are 33 active equity funds with assets exceeding 10 billion yuan, with E Fund Blue Chip Select leading at 36.413 billion yuan [2] - Most of these funds have achieved positive returns over the past year, with notable performances such as Yongying Technology Smart Mixed Fund returning approximately 270% [2] - Other funds like China Europe Digital Economy Mixed Fund and Yongying Advanced Manufacturing Smart Mixed Fund also reported returns of 181.08% and 136.49% respectively [2] Group 2: Scale Changes and Market Dynamics - Despite strong performance, over half of the large-cap active equity funds have experienced a decline in scale, with 10 funds seeing reductions of over 20% [4] - The difficulty in adjusting positions for larger funds and the growing preference for ETFs among investors have contributed to this trend [4] - A fund manager noted that sustained long-term performance is crucial for retaining investors [4] Group 3: Future Strategies and Market Outlook - Fund managers are focusing on sectors like domestic consumption, technology, and high-end manufacturing for the fourth quarter [5][6] - E Fund Blue Chip Select's manager emphasizes the importance of free cash flow and intrinsic value accumulation in driving market capitalization growth [5] - The manager of Xinchuan He Run Fund highlights the positive interaction between fundamentals and liquidity, suggesting a potential market trend reversal [6]

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical and biotechnology industry [1]. Core Insights - The 2025 National Medical Insurance negotiation has commenced, with a focus on innovative drugs and a significant increase in the number and quality of applications for drugs outside the basic medical insurance directory [17][18]. - The report highlights a robust performance of the pharmaceutical sector, with the A-share pharmaceutical index showing a year-to-date increase of 21.1%, outperforming the CSI 300 index by 3.17% [4][9]. - The report emphasizes the long-term growth potential of China's innovative drug market, driven by a large patient pool, favorable policies, and a strong pipeline of innovative drugs [16]. Summary by Sections 1. Industry Performance - The A-share pharmaceutical index has increased by 1.31% this week and 21.1% year-to-date, with significant outperformance against the CSI 300 index [4][9]. - The Hang Seng Healthcare Index has shown a year-to-date increase of 73.53%, outperforming the Hang Seng Technology Index by 40.06% [4][9]. 2. R&D Progress and Company Dynamics - Pfizer has initiated two global Phase III clinical studies for PD-1/VEGF dual antibodies, targeting non-small cell lung cancer and colorectal cancer [4]. - The report notes that 310 generic names have passed the formal review for inclusion outside the basic medical insurance directory, marking a 24.5% increase from 2024 [18]. 3. Industry Insights and Regulatory Developments - The report ranks favored sub-industries as follows: innovative drugs > research services > CXO > traditional Chinese medicine > medical devices > pharmacies [10][12]. - The report identifies key companies to watch, including Innovent Biologics, BeiGene, and Hengrui Medicine, among others, for their strong clinical competitiveness [12][18]. 4. Market Review - The report indicates that the pharmaceutical sector's adjustment has narrowed, with some sub-industries experiencing slight rebounds [4][9]. - The report provides a detailed overview of stock performance, highlighting significant gainers and losers in the A-share and H-share markets [4][9].

10月最后一个交易日（10月31日），沉寂已久的创新药板块突然大爆发，A港同频共振。重仓A股创新 药的药ETF（562050）场内劲涨2.46%，三生国健20CM涨停。港股创新药尽显高弹性，100%创新药研 发标的——港股通创新药ETF（520880）放量上探5.25%！成份股三生制药、映恩生物-B领涨11%。 回到二级市场来看，创新药阶段性调整已持续两个月有余，时间已较为充分，部分龙头品种或已进入绝 对收益区间。后续创新药行情或将逐步过渡到关注"质量因子"的第二阶段，从资金驱动转向基本面驱 动，优质标的的价值将深化，龙头白马有望占优。 【创新药"新势力"——港股通创新药ETF（520880）：纯正创新药，聚焦真龙头，港股高弹性】 港股通创新药ETF（520880）被动跟踪恒生港股通创新药精选指数，该指数完全不含CXO，100%布局 创新药研发类公司，超7成仓位押注大市值创新药龙头，是精准表征创新药硬核力量的纯正创新药指 数。场外投资者可关注其联接基金：025221。 | | | 港股通创新药ETF (520880) 标的指数 | | | --- | --- | --- | --- | | | | 前十成份股 ...

Group 1 - The core viewpoint of the articles discusses the historical market trends in November and year-end, highlighting a shift from "pricing current fundamentals" from April to October to "pricing expectations" from November to March of the following year [1][5] - Historical data indicates that the correlation between market performance in November and fundamentals is weak, often showing a negative correlation, as October is a strong earnings month leading to a need for market correction [1][5] - The market style in November tends to favor small-cap and growth stocks while value and stability lag behind, reflecting a trend of speculative investments in smaller themes [1][5] Group 2 - The year-end market performance is characterized by a search for future economic clues, leading to a revaluation of various industries based on next year's economic expectations [2][3] - The technology and high-end manufacturing sectors are expected to continue their growth momentum, becoming key areas for economic exploration in the coming year [2][3] - The "anti-involution" policies are expected to enhance cyclical sectors, with more areas showing marginal improvement trends, providing room for valuation recovery [2][3] Group 3 - The market is anticipated to enter a more balanced phase with a focus on technology growth, compared to the previous quarter [3] - The scarcity of high-growth sectors has led to increased investor focus on AI, with public funds heavily weighted towards the TMT sector, reaching historical highs [3][6] - As earnings reports conclude, the market is expected to shift focus towards next year's performance expectations and industry trends, leading to a more active thematic investment phase [5][6]

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical sector [7] Core Views - The pharmaceutical sector has shown resilience with a 1.2% increase in the CITIC Pharmaceutical Index, outperforming the CSI 300 Index by 1.6 percentage points during the week of October 27-31, 2025 [3][54] - The overall revenue growth for the pharmaceutical sector in Q1-Q3 2025 was -2%, with a net profit decline of -1%. However, Q3 2025 showed signs of improvement with a 0% revenue growth and a -3% net profit growth compared to Q2 2025 [4][17] - The report highlights the strong performance of innovative drugs, CXO, and upstream sectors, indicating a positive outlook for these segments [4][25] Summary by Sections Weekly Market Review - The CITIC Pharmaceutical Index increased by 1.2% during the week, ranking 13th among CITIC's primary industry classifications. Year-to-date, the index has risen by 22%, also ranking 13th [3][54] - The top five performing stocks for the week included HeFu China (+49.0%), NuoSiGe (+36.7%), SanSheng GuoJian (+33.1%), ChangShan Pharmaceutical (+29.6%), and ZhenDe Medical (+26.6%) [3][70] Q3 Performance Overview - The pharmaceutical sector's overall revenue growth for Q3 2025 was 0%, with a net profit decline of -3%. The highest revenue growth was seen in Bio-Tech, Bio-Pharma, and home-use devices [4][17] - The report notes that the Bio-Pharma segment has consistently shown strong revenue growth since Q1 2023, indicating a robust performance trend [18][25] Subsector Analysis 1. **BioPharma/Biotech** - Q3 2025 saw significant growth due to multiple innovative drug approvals, with expectations for continued high growth in 2026 [25] 2. **Pharma** - The sector faced challenges with a -1% revenue decline in Q3 2025, but upcoming healthcare negotiations may provide revenue boosts [26] 3. **CXO** - The CXO sector reported a 10% revenue increase and a 51% net profit increase in Q3 2025, with a positive outlook for Q4 and 2026 [31] 4. **Upstream** - The upstream sector's revenue reached 4.4 billion yuan in Q3 2025, showing a 13.1% year-on-year growth, with expectations for further growth in 2026 [30] 5. **Medical Devices** - The medical devices sector reported a 10.6% revenue increase in Q3 2025, with a positive outlook for continued growth [41] Recommendations - The report suggests focusing on high-quality innovative drug leaders and the CXO sector, particularly companies like SanSheng Pharmaceutical, XinDa Bio, and Kangfang Bio [5][25]